BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 12, 2023
Distillery Therapeutics

MANF for inherited kidney disease

BioCentury | Apr 29, 2021
Distillery Therapeutics

Inhibiting RNA epigenetic enzyme METTL3 for polycystic kidney disease

DISEASE CATEGORY: Renal
INDICATION: Polycystic kidney disease (PKD) Targeting METTL3, which creates N6-methyladenosine (m6A) modifications on RNA, could treat autosomal dominant polycystic
BioCentury | Aug 28, 2019
Translation in Brief

Nanoparticles targeting CRISPR to cancer

Boston Children’s team’s system targets gene editing therapies to triple negative breast cancer cells
BioCentury | Jun 14, 2017
Distillery Techniques

Assays and screens

BioCentury | Mar 16, 2017
Targets & Mechanisms

Bone appétit!

How a bone hormone could help treat obesity
BioCentury | Mar 15, 2017
Distillery Therapeutics

Endocrine / Metabolic

BioCentury | Jan 12, 2017
Translation in Brief

Iron age arms race

Fighting bacteria with their own defensive molecules
Items per page:
1 - 10 of 47